8780544

Source:http://linkedlifedata.com/resource/pubmed/id/8780544

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0014792, umls-concept:C0030705, umls-concept:C0032433, umls-concept:C0035020, umls-concept:C0035647, umls-concept:C0037874, umls-concept:C0441889, umls-concept:C0600139
pubmed:issue	5
pubmed:dateCreated	1996-10-8
pubmed:abstractText	Androgen deprivation is currently the standard treatment for patients with metastatic prostate carcinoma. Few reliable prognostic markers are able to select, at diagnosis, patients who will respond favorably and durably to hormone ablation. Circulating polyamines, markers of cell proliferation that are elevated in prostate carcinoma, have been evaluated as a prognostic tool.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0374236
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Androgen Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Gonadotropin-Releasing Hormone, http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen, http://linkedlifedata.com/resource/pubmed/chemical/Spermine
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	0008-543X
pubmed:author	pubmed-author:BansardJ YJY, pubmed-author:CipollaB GBG, pubmed-author:GuilléFF, pubmed-author:LobelBB, pubmed-author:MoulinouxJ PJP, pubmed-author:QuemenerVV, pubmed-author:StaermanFF, pubmed-author:ZiadeJJ
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	78
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1055-65
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:8780544-Aged, pubmed-meshheading:8780544-Aged, 80 and over, pubmed-meshheading:8780544-Androgen Antagonists, pubmed-meshheading:8780544-Bone Neoplasms, pubmed-meshheading:8780544-Erythrocytes, pubmed-meshheading:8780544-Follow-Up Studies, pubmed-meshheading:8780544-Gonadotropin-Releasing Hormone, pubmed-meshheading:8780544-Humans, pubmed-meshheading:8780544-Male, pubmed-meshheading:8780544-Middle Aged, pubmed-meshheading:8780544-Multivariate Analysis, pubmed-meshheading:8780544-Neoplasm Recurrence, Local, pubmed-meshheading:8780544-Orchiectomy, pubmed-meshheading:8780544-Predictive Value of Tests, pubmed-meshheading:8780544-Prognosis, pubmed-meshheading:8780544-Prostate-Specific Antigen, pubmed-meshheading:8780544-Prostatic Neoplasms, pubmed-meshheading:8780544-Spermine, pubmed-meshheading:8780544-Survival Rate
pubmed:year	1996
pubmed:articleTitle	Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.
pubmed:affiliation	Department of Urology, Université de Rennes, France.
pubmed:publicationType	Journal Article